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P R E V I E W SDiscovering orphans’ sweet secret:
NR4A receptors and hepatic glucose production
Aberrant hepatic gluconeogenesis contributes importantly to hyperglycemia in type II diabetic patients. A study by Pei et al.
(2006b) identifies NR4A orphan nuclear receptors as a novel branch of cAMP-dependent regulators of hepatic glucose
production under healthy and diabetic conditions.With around 200 million people affected
worldwide, the incidence of type II diabe-
tes has reached pandemic dimensions.
As a hallmark of the type II diabetic
phenotype, peripheral insulin resistance
promotes chronic hyperglycemia, which
represents a major cause of vascular
complications and relies substantially on
unrestricted de novo glucose synthesis
(gluconeogenesis) in the liver of these
patients. In this metabolic setting, a con-
comitant predominance of counterregu-
latory hormones—in particular, pancre-
atic glucagon acting via the intracellular
cAMP pathway—further aggravates he-
patic glucose production (Saltiel, 2001).
Deciphering how counterregulatory hor-
mones regulate hepatic glucose output
represents amajor challenge for the iden-
tification of potential new therapeutic
targets. Recent work by Pei and col-
leagues (2006b) advances our under-
standing of gluconeogenic control by
investigating the role of NR4A orphan
nuclear receptors in liver metabolism.
In healthy subjects, gluconeogenesis
is synergistically triggered through rising
plasma levels of glucagon and glucocor-
ticoid hormones during fasting to ensure
a constant glucose supply for extrahe-
patic tissues. Gluconeogenic pathway
activity is mainly determined through
transcriptional induction of rate-limiting
key enzyme genes, such as phospho-
enolpyruvate carboxykinase (PEPCK)
and glucose-6-phosphatase (G6Pase)
(Saltiel, 2001).
cAMP-element-bindingprotein (CREB)
has been identified as a critical transcrip-
tional checkpoint for the induction of
hepatic gluconeogenesis in response to
cAMP. Mice lacking hepatic CREB activ-
ity show substantially diminished blood
glucose levels and reduction of gluco-
neogenic enzyme gene expression. In-
deed, CREB action accounts for the syn-
ergistic activation of the gluconeogenic
program by glucagon and glucocorticoid
signals through the transcriptional induc-
tion of the nuclear-receptor coactivatorCELL METABOLISM : NOVEMBER 2006PGC-1a. PGC-1a, in turn, coactivates
the glucocorticoid receptor nuclear re-
ceptor HNF-4 as well as the forkhead
transcription factor Foxo1 on PEPCK and
G6Pase gene promoters, thereby estab-
lishing themajor regulatory axis of cAMP-
dependent glucose production in the liver
(Herzig et al., 2001; Puigserver et al.,
2003; Yoon et al., 2001). However, PGC-
1a-deficient hepatocytes still exhibit a
certain degree of cAMP-inducible gluco-
neogenic activity, suggesting that control
over this pathway by cAMP does not de-
pend exclusively on this coactivator (Lin
et al., 2004).
Expression of orphan nuclear recep-
tors of the NR4A family (Nurr1, Nurr77,
and Nor1) is rapidly induced upon a vari-
ety of external stimuli and has been
shown to control cell proliferation, apo-
ptosis, and neuronal differentiation. In
contrast to classical ligand-activated
nuclear receptors, studies to date have
offered only very limited insights into the
function of these factors for energy
metabolism (Maxwell andMuscat, 2006).
Coincident with the notion that NR4A
transcriptional activities are largely de-
termined by their expression levels (Max-
well and Muscat, 2006), Pei and col-
leagues (2006b) found that all NR4A
family members are induced upon cAMP
treatment of isolated hepatocytes as well
as in livers of fasted and glucagon-
challenged mice in a CREB-dependent
manner. These findings prompted the
authors to explore a potential role of
NR4A receptors in cAMP-dependent he-
patic energy metabolism. Indeed, NR4A
overexpression in hepatocytes substan-
tially enhances the expression of multiple
genes within the gluconeogenic path-
way, most notably enolase 3 and fruc-
tose-bisphosphatase 1 and 2 (FBP1/2).
Remarkably, the authors were able to
distinguish three distinct sets of glucore-
gulatory targets in the liver, responding to
NR4A, PGC-1a, or both in an additive
manner, arguing for a distinct, comple-
mentary mode of action of NR4A factorsapart from the established CREB-PGC-
1a axis. Consistently, NR4A receptors
do not influence expression of PGC-1a
itself or its target gene PEPCK, nor does
PGC-1a function as a physical NR4A co-
factor in transcriptional activation studies
(Pei et al., 2006b). The NR4A nuclear-
receptor family, therefore, represents a
novel, PGC-1a-independent branch of
cAMP/CREB-mediated glucosemetabo-
lism in the liver (Figure 1).
Remarkably, Pei and colleagues
(2006b) observed a substantial induction
of NR4A mRNA expression levels in
type 1 and type 2diabeticmousemodels.
Furthermore, acute ablation ofNR4A liver
function in type II diabetic db/db mice
by adenoviral delivery of a dominant-
negative Nur77 decreased expression of
gluconeogenic target genes and restored
elevated glucose levels to near normal
(Pei et al., 2006b), suggesting an instru-
mental role of the hepatic CREB/NR4A
pathway in the manifestation of diabetic
hyperglycemia.
Apart from hyperglycemia, a subacute
inflammation represents an additional
characteristic feature of insulin-resistant
type II diabetes, driven at least in part by
the proinflammatory response of macro-
phages (Saltiel, 2001). In this respect, pre-
vious results from the Tontonoz lab dem-
onstrated thatNR4A receptors induce the
production of proinflammatory cytokines
in these cells (Pei et al., 2006a). A prodia-
betic liver function of NR4A receptors
might, therefore, also point to a more
general role of these factors in the promo-
tion of the type II diabetic phenotype.
Some questions arise. What is the
mode of cooperativity between the
NR4A and PGC-1a pathways? The dis-
tinction between individual liver targets
argues for specific promoter-dependent
setups rendering a gene responsive to
NR4A, PGC-1a, or both. Noteworthy,
PGC-1a has been shown to coactivate
Nurr1 in other cell types (Nervina et al.,
2006), an effect not observed by Pei and
colleagues (2006b), further strengthening339
P R E V I E W Sthe case for a cell- or promoter-specific
connection between NR4A and PGC-1a.
What is the connection to insulin signal-
ing? Insulin exerts a dominant-negative
effect on gluconeogenesis in response
to exogenous glucose, and defects in he-
patic insulin signaling lead to hyperglyce-
mia and impaired glucose tolerance
(Michael et al., 2000). It will be interesting
to determine whether the NR4A pathway
is actively inhibited by insulin as shown
for PGC-1a (Puigserver et al., 2003) or
Figure 1. cAMP controls hepatic gluconeogenesis
via two distinct transcriptional effector pathways
Pei and colleagues (2006b) show that the cAMP-
responsive transcription factor CREB promotes
hepatic glucose output through the independent
induction of coactivator PGC-1a and NR4A orphan
nuclear receptors. PGC-1a and NR4A receptors, in
turn, stimulate the expression of common as well
as distinct targets within the gluconeogenic path-
way to trigger hepatic glucose release during fasting
and under diabetic conditions.340just passively shuts off in response to
declining cAMP levels upon food con-
sumption. Finally, what is the molecular
mechanism of NR4A upregulation in dia-
betic mice? Given the causal relation-
ship between elevated NR4A levels and
hyperglycemia, the mechanisms of NR4A
receptor induction under these condi-
tions are of particular importance for
putative therapeutic intervention strate-
gies. In any case, potential therapeutic
benefits of NR4A inhibition in the liver
for counteracting diabetic hyperglycemia
would need to be balanced by possible
effects on other metabolic pathways in
or outside of the liver, or by effects on
apoptosis or cell proliferation.
In conclusion, the recent paper by Pei
and colleagues (2006b) provides an
important insight into novel aspects of
signal-dependent control of glucose
metabolismconnected todiabetic patho-
physiology. The discovery of the NR4A
branch of cAMP-mediated metabolic
control will provide a sweet incentive for
investigators to follow up on this issue.
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